Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPT1G in AML and High-Risk MDS
NCT07107126Phase 1Recruiting
- Sponsor
- Remedy Plan Therapeutics
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RPT1G in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 cohorts), sponsored by Remedy Plan Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 3 years and Adverse Events at 3 years. Started Feb 2026; status: recruiting.
02
Drugs
RPT1G
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07107126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107126.